Tocilizumab
Colitis
Herlev Hospitalmonoclonal_antibodyN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 89/ 100
Competitive context
6 Active assets in the Colitis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Infliximab Therakos LLC | Phase 2 | B |
Vedolizumab Therakos LLC | Phase 2 | B |
Mesalamine National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 | CCC |
MERCAPTOPURINE ANHYDROUS National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 | CCC |
TACROLIMUS National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 | CCC |
View all 13 →
Same molecule, other indications
Tocilizumab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →